The lipid panel measures fats circulating in blood — total cholesterol, LDL cholesterol (“bad cholesterol”; main target for CVD risk reduction), HDL cholesterol (“good cholesterol”; higher better), and triglycerides. Non-HDL cholesterol (total minus HDL) is an alternative target. ADA recommends annual lipid panel for adults with diabetes; more often if abnormal. Adults with type 2 diabetes have 2-4 fold higher cardiovascular disease risk than non-diabetic peers due to diabetic dyslipidemia (high triglycerides, low HDL, increased small dense LDL), insulin resistance effects on lipid metabolism, chronic hyperglycemia damaging blood vessels, and often coexisting hypertension and obesity. ADA lipid targets: LDL under 100 mg/dL standard, under 70 with established CVD, under 55 with very high risk; non-HDL under 130 standard, under 100 with CVD; HDL over 40 (men) or 50 (women); triglycerides under 150. Statin therapy is recommended for most adults with diabetes age 40-75 — moderate intensity at minimum; high intensity for established CVD. Add ezetimibe if LDL not at target; PCSK9 inhibitors (Repatha, Praluent) for adults not achieving target on statins; bempedoic acid for statin intolerance; icosapent ethyl (Vascepa) for adults with triglycerides 150-499 on statin therapy (REDUCE-IT trial). Improve glucose control to improve triglycerides and HDL; weight loss, exercise, diet improve all lipid measures.
Normal vs Target Values
| Measure | General “Normal” | Diabetes Target | Diabetes + CVD Target |
|---|---|---|---|
| Total cholesterol | under 200 mg/dL | under 200 | under 180 |
| LDL | under 130 mg/dL | under 100 | under 70 (or under 55 very high risk) |
| HDL (men) | over 40 mg/dL | over 40 (higher better) | over 40 (higher better) |
| HDL (women) | over 50 mg/dL | over 50 (higher better) | over 50 (higher better) |
| Triglycerides | under 150 mg/dL | under 150 | under 150 |
| Non-HDL | under 160 mg/dL | under 130 | under 100 |
| LDL particle number | under 1,000 nmol/L | under 1,000 | under 1,000 |
Diabetic Dyslipidemia Pattern
- Elevated triglycerides (often 150-400 mg/dL).
- Low HDL cholesterol.
- LDL particles tend to be smaller and denser (more atherogenic).
- Apolipoprotein B (ApoB) elevated.
- LDL particle number (LDL-P) elevated.
- Total cholesterol may be normal — masking the atherogenic pattern.
- Improves with: glucose control, weight loss, exercise, low-carb or Mediterranean diet.
- SGLT2 inhibitors modestly improve lipids.
- GLP-1 agonists modestly improve lipids.
Statin Therapy
- ADA: most adults with diabetes age 40-75 should be on statin.
- Moderate intensity: atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg.
- High intensity: atorvastatin 40-80 mg, rosuvastatin 20-40 mg.
- Indication for high intensity: established CVD, multiple risk factors.
- LDL reduction: 30-50% (moderate) or 50%+ (high intensity).
- Monitor for muscle aches (myalgia) and liver enzymes.
- Coenzyme Q10 supplementation for statin myalgia — modest evidence.
- Switch statins if intolerance — many adults tolerate different statin.
- Pregnancy: contraindicated; switch before conception.
Beyond Statins
- Ezetimibe (Zetia): blocks cholesterol absorption; add to statin if LDL not at target.
- PCSK9 inhibitors (Repatha, Praluent): injectable; very effective LDL reduction; for those not at target on statin + ezetimibe.
- Bempedoic acid (Nexletol): oral; alternative for statin intolerance.
- Icosapent ethyl (Vascepa): prescription EPA; for triglycerides 150-499 on statin (REDUCE-IT trial).
- Fenofibrate: for severe hypertriglyceridemia (over 500); pancreatitis prevention.
- Niacin: rarely used now; modest HDL improvement but cardiovascular trials negative.
- Bile acid sequestrants: occasional use; cholestyramine, colesevelam.
- Inclisiran (Leqvio): twice-yearly injection; PCSK9 inhibitor.
Lifestyle Improvement
- Mediterranean diet — best evidence for lipid improvement.
- Reduce saturated fat to under 10% of calories.
- Eliminate trans fats.
- Increase omega-3 fatty acids (fish 2x weekly).
- Soluble fiber (oats, beans, fruits) lowers LDL.
- Plant sterols/stanols supplements modestly lower LDL.
- Aerobic exercise 150+ min/week — raises HDL, lowers triglycerides.
- Weight loss — improves all lipid measures.
- Alcohol moderation — excess raises triglycerides.
- Smoking cessation — improves HDL.
- Limit refined carbohydrates — lowers triglycerides.
Triglycerides and Diabetes
- Often elevated in adults with diabetes.
- Strongly affected by carbohydrate intake.
- Improvements with glucose control.
- Severe hypertriglyceridemia (over 500): pancreatitis risk.
- Fenofibrate for severe elevation.
- Icosapent ethyl (Vascepa) for moderate elevation on statin.
- Low-carb diets significantly improve triglycerides.
- Weight loss improves triglycerides.
- Limit alcohol — major triglyceride raiser.
- Aerobic exercise lowers triglycerides.
How to Prepare
- Fast 9-12 hours before test (water allowed).
- Schedule for morning to minimize fasting impact.
- Continue regular medications.
- Note recent illnesses (acute illness can affect results).
- Avoid heavy alcohol use day before.
- Bring list of medications including supplements.
- Bring previous lipid results for comparison.
- Some labs offer non-fasting lipid panel — discuss with provider.
The Bottom Line
The lipid panel measures fats circulating in blood — total cholesterol, LDL (“bad cholesterol”; main target for CVD risk reduction), HDL (“good cholesterol”; higher better), and triglycerides. ADA recommends annual lipid panel for adults with diabetes. Adults with type 2 diabetes have 2-4 fold higher cardiovascular disease risk due to diabetic dyslipidemia (high triglycerides, low HDL, increased small dense LDL particles), insulin resistance, chronic hyperglycemia, and often coexisting hypertension and obesity. ADA lipid targets tiered by risk: LDL under 100 mg/dL standard, under 70 with established CVD, under 55 with very high risk; non-HDL under 130 standard, under 100 with CVD; HDL over 40 (men) or 50 (women); triglycerides under 150. Statin therapy is recommended for most adults with diabetes age 40-75 — moderate intensity (atorvastatin 10-20, rosuvastatin 5-10) at minimum; high intensity (atorvastatin 40-80, rosuvastatin 20-40) for established CVD; LDL reduction 30-50% or 50%+. Beyond statins: ezetimibe (add if not at target), PCSK9 inhibitors (Repatha, Praluent — injectable, very effective), bempedoic acid (for statin intolerance), icosapent ethyl/Vascepa (for triglycerides 150-499 on statin; REDUCE-IT trial), fenofibrate (severe hypertriglyceridemia). Lifestyle improvement: Mediterranean diet (best evidence), reduce saturated fat under 10%, eliminate trans fats, omega-3 fish 2x weekly, soluble fiber, aerobic exercise 150+ min weekly raises HDL and lowers triglycerides, weight loss improves all measures, alcohol moderation, smoking cessation, limit refined carbohydrates lowers triglycerides. Improve glucose control to improve triglycerides and HDL. SGLT2 inhibitors and GLP-1 agonists modestly improve lipids. Triglycerides over 500 carry pancreatitis risk and warrant specific treatment. For adults with type 2 diabetes, annual lipid monitoring and aggressive lipid management is critical for cardiovascular disease prevention — the leading cause of death in diabetes. See our broader diabetes and cholesterol guide for context.
